Peter S. Greenleaf - 27 Feb 2026 Form 4 Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)

Role: Chief Executive Officer, Director
Signature: /s/ Peter S. Greenleaf
Issuer symbol: AUPH
Transactions as of: 27 Feb 2026
Net transactions value: -$1,433,647
Form type: 4
Filing time: 03 Mar 2026, 16:13:51 UTC
Previous filing: 23 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Greenleaf Peter	Chief Executive Officer, Director	#140, 14315-118 AVENUE, EDMONTON, ALBERTA, CANADA	/s/ Peter S. Greenleaf	03 Mar 2026	0001363683

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AUPH	Common Stock	Award	$0	+196,403	+11%	$0.000000	1,941,269	27 Feb 2026	Direct	F1
transaction	AUPH	Common Stock	Tax liability	$1,433,647	-100,890	-5.2%	$14.21	1,840,379	02 Mar 2026	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AUPH	Employee Stock Option (right to buy)	Award	$0	+328,424		$0.000000	328,424	27 Feb 2026	Common Stock	328,424	$13.97	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement.
F2	Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units.
F3	One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.